MetaCap

CRISPR Therapeutics (CRSP) vs Denali Therapeutics (DNLI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Denali Therapeutics (DNLI) has outperformed CRISPR Therapeutics (CRSP) over the past year, gaining 2.5% versus a loss of 22.2%. Over five years, CRSP leads with a -50.4% price change compared with -59.0% for DNLI. CRISPR Therapeutics is the larger company by market cap ($3.79 billion vs $2.96 billion), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRSP-22.16%DNLI+2.50%
+55%+14%-26%
Nov 21, 20251 yearNov 20, 2026
CRSP-52.57%DNLI-60.84%
+6%-37%-79%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRSP versus DNLI key metrics
MetricCRSPDNLI
Share price$39.10$18.45
Market cap$3.79B$2.96B
1-day change+0.44%+1.37%
YTD return-25.44%+11.75%
1-year return-22.16%+2.50%
5-year return-50.37%-59.02%
EPS (TTM)$-4.73$-1.72
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$3.51M$0
Revenue growth (YoY)-90.59%—
Net income (latest FY)$-581.60M$-512.54M
Operating margin-18933.65%—
Net margin-16569.77%—
52-week high$63.45$27.30
52-week low$38.15$15.34
Distance from 52-week high-38.38%-32.42%
Analyst consensusbuystrong_buy
Avg. price target upside+118.47%+94.15%
Average volume1.74M1.68M
Shares outstanding97.00M160.29M
Employees—503
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DNLI has outperformed CRSP by 24.7 percentage points over the past year.

About CRISPR Therapeutics

CRSP stock →

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

About Denali Therapeutics

DNLI stock →

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees

CRSP vs DNLI FAQ

Which is bigger, CRISPR Therapeutics or Denali Therapeutics?

CRISPR Therapeutics (CRSP) is larger, with a market capitalization of $3.79B compared with $2.96B for Denali Therapeutics (DNLI).

Which stock has performed better over the past year, CRSP or DNLI?

DNLI returned +2.50% over the past 12 months, compared with -22.16% for CRSP (price return, excluding dividends). Past performance does not predict future results.

Are CRISPR Therapeutics and Denali Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons